title: [Interferon alfa-2b treatment of adult patients during early chronic phase of Ph1-positive chronic myeloid leukemia (initial report on a cooperative study, protocol CML-MIG-97)].
abstract: OBJECTIVE
  Evaluation of clinical effectiveness of two regimens of induction therapy of an early chronic stage of Ph'-positive chronic myeloid leukemia including interferon-alpha 2b (intron-A, "Schering Plough") in a cooperative randomised trial on the protocol CML MIG-97.
  
  
  METHODS
  42 patients with chronic myeloid leukemia were treated either with intron-A in standard doses (5 IU/m2/day) alone or in combination with monthly 10-day courses of low-dose cytosine-arabinoside (10 mg/m2/twice a day). The effect was assessed by the international criteria of a complete and partial hematologic remission and the cytogenetic response.
  
  
  RESULTS
  Intron-A therapy in standard doses produced a pronounced cytogenetic response in 28.6% of the patients. In low-dose interferon-alpha-2b (reaferon and intron-A, 1-3 IU/m2/day) in combination with various regimens of chemotherapy only minimal cytogenetic response was achieved.
  
  
  CONCLUSIONS
  A pronounced cytogenetic response in early chronic stage of CML to standard doses of intron A holds promise in prolongation of CML patients survival and design of new effective therapy programs.
authors.forename: N D
authors.initials: ND
authors.lastname: Khoroshko
authors.forename: A G
authors.initials: AG
authors.lastname: Turkina
authors.forename: A V
authors.initials: AV
authors.lastname: Zakharova
authors.forename: Iu N
authors.initials: IuN
authors.lastname: Kobzev
authors.forename: E V
authors.initials: EV
authors.lastname: Domracheva
authors.forename: L Iu
authors.initials: LIu
authors.lastname: Tikhonova
authors.forename: E A
authors.initials: EA
authors.lastname: Semenova
authors.forename: V S
authors.initials: VS
authors.lastname: Zhuravlev
authors.forename: M A
authors.initials: MA
authors.lastname: Sokolova
authors.forename: S V
authors.initials: SV
authors.lastname: Kuznetsov
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003582:Cytogenetics; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012074:Remission Induction; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins